Stockscreener 앱 받기
6.15
5.31%
0.31
시간 외 거래:
6.50
0.35
+5.69%
전일 마감가:
$5.84
열려 있는:
$5.8
하루 거래량:
994.23K
Relative Volume:
3.28
시가총액:
$480.64M
수익:
$14.02M
순이익/손실:
$-84.03M
주가수익비율:
-2.4023
EPS:
-2.56
순현금흐름:
$-125.54M
1주 성능:
+0.49%
1개월 성능:
+5.67%
6개월 성능:
+42.69%
1년 성능:
+25.25%
1일 변동 폭
$5.66
$6.48
1주일 범위
$5.62
$6.48
52주 변동 폭
$3.85
$7.60
Meiragtx Holdings Plc Stock (MGTX) Company Profile
명칭
Meiragtx Holdings Plc
전화
646-860-7985
주소
450 EAST 29TH STREET, NEW YORK, NY
MGTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MGTX
Meiragtx Holdings Plc
|
6.15 | 480.64M | 14.02M | -84.03M | -125.54M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Meiragtx Holdings Plc Stock (MGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-31 | 재개 | Chardan Capital Markets | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-09-15 | 재개 | BofA Securities | Buy |
| 2019-09-03 | 개시 | Piper Jaffray | Overweight |
| 2019-02-27 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-03 | 개시 | Barclays | Overweight |
| 2018-07-03 | 개시 | BofA/Merrill | Buy |
모두보기
Meiragtx Holdings Plc 주식(MGTX)의 최신 뉴스
(MGTX) Trading Signals - Stock Traders Daily
MeiraGTx (NASDAQ:MGTX) Trading Up 10.1%What's Next? - MarketBeat
BNP Paribas Financial Markets Raises Stock Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
MeiraGTx's SWOT analysis: gene therapy firm's stock faces clinical hurdles - Investing.com
Garden State Investment Advisory Services LLC Invests $1.64 Million in MeiraGTx Holdings plc (NASDAQ:MGTX) - MarketBeat
Investors in MeiraGTx Holdings (NASDAQ:MGTX) have unfortunately lost 71% over the last five years - Yahoo Finance
MetLife Investment Management LLC Reduces Position in MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
MeiraGTx's SWOT analysis: gene therapy firm's stock faces pivotal year By Investing.com - Investing.com Nigeria
MeiraGTx granted RMAT designation by U.S. FDA to AAV2-hAQP1 - Yahoo Finance
Learn to Evaluate (MGTX) using the Charts - Stock Traders Daily
FDA grants RMAT status to MeiraGTx's xerostomia gene therapy By Investing.com - Investing.com Canada
FDA grants RMAT status to MeiraGTx's xerostomia gene therapy - Investing.com India
MeiraGTx Secures Coveted FDA RMAT Status for Breakthrough Xerostomia Gene Therapy - StockTitan
MeiraGTx Holdings: Behind The Recent Rally (NASDAQ:MGTX) - Seeking Alpha
Erste Asset Management GmbH Takes $2.80 Million Position in MeiraGTx Holdings plc (NASDAQ:MGTX) - MarketBeat
MeiraGTx (NASDAQ:MGTX) Shares Gap UpHere's Why - MarketBeat
Knoll Capital Management LLC Buys Shares of 1,250,000 MeiraGTx Holdings plc (NASDAQ:MGTX) - MarketBeat
Chardan Capital Reiterates Buy Rating for MeiraGTx (NASDAQ:MGTX) - Defense World
Trend Tracker for (MGTX) - Stock Traders Daily
Analysts Have Lowered Expectations For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its Latest Results - Simply Wall St
MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
MeiraGTx Holdings Reports Significant Losses Amid Strategic Moves - TipRanks
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates - MSN
MeiraGTx wins 3 Rare Pediatric designations and updates on AAV-AIPL1 - The Pharma Letter
MeiraGTx Holdings plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MeiraGTx Holdings PLC Q3 2024 Earnings: Revenue Soars to $10.9M, EPS Misses Estimates at -$0.55 - GuruFocus.com
MeiraGTx Scores Triple FDA Designations, Reports Strong Parkinson's Data Despite Q3 Loss | MGTX Stock News - StockTitan
Jim Cramer: This Tech Stock Is A Buy, SoFi Technologies Is Good - Benzinga
Dynamic range: the key to MeiraGTx’s quest to control genes with pills - BioCentury
Duchenne Muscular Dystrophy Therapeutics Market Trends, Growth Insights, and Forecasts 2033 - WhaTech
Gene Therapy Market Detailed Analysis and Forecast to 2031 - InsightAce Analytic
Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity - BioWorld Online
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress - The Manila Times
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? - MSN
(MGTX) Long Term Investment Analysis - Stock Traders Daily
Cell therapy weekly: US$225 million investment towards world-class research institute - RegMedNet
MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study - Clinical Trials Arena
MeiraGTx Holdings plc Inc. (MGTX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study - Yahoo Finance
MeiraGTx Holdings Reports Promising Parkinson’s Therapy Results - Yahoo Finance
Items Tagged with 'glutamic acid decarboxylase' - BioWorld Online
Items Tagged with 'AAV-GAD' - BioWorld Online
Meiragtx looks to a phase III in Parkinson’s - BioWorld Online
Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints - AOL
MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings (NASDAQ:MGTX) - Seeking Alpha
MeiraGTx (MGTX) Sees Stock Surge After Clinical Results News - Stocks Telegraph
MeiraGTx stock gains on Parkinson’s drug data (NASDAQ:MGTX) - Seeking Alpha
Investors in MeiraGTx Holdings (NASDAQ:MGTX) from three years ago are still down 75%, even after 13% gain this past week - Simply Wall St
MeiraGTx reports positive Parkinson's gene therapy trial results By Investing.com - Investing.com UK
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease - The Manila Times
Meiragtx Holdings Plc (MGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):